Agenda

• Evaluating the role of liver-directed metabolic therapies in addressing interconnected drivers of steatosis, inflammation and fibrosis to enhance therapeutic impact, enabling more comprehensive disease management and improving long-term patient outcomes
• Modulating liver-specific metabolic pathways to improve lipid handling and reduce inflammatory signaling, strengthening anti-fibrotic efficacy and improving disease resolution potential 
• Developing differentiated metabolic therapies with scalable combination potential to address persistent unmet need in MASH, improving treatment durability and future therapeutic positioning

• Our Discovery Platform leverages disease Atlases and deep learning to connect disease biology to chemical matter through transcriptomics
• Cellarity is leveraging our differentiated platform to identify novel druggable nodes to tackle advanced fibrotic disease in MASH
• Cellarity generated the largest human whole liver MASH Atlas to date. We established a highly relevant human in vitro model to capture the disease related signatures identified in our Atlas and that phenotypically captures multiple features of stellate activation including fibrogenesis & inflammation. Using our platform, we identified and validated essential processes causing disease-related cell dysfunction by testing predictions in vitro

•  Leveraging multi-modal patient data and AI to discover relevant pathways improving target prioritization and accelerating development decision-making
• “Integrating AI/ML with high-dimensional assays to discover novel targets” Leveraging deep biological datasets to build differentiated strategies and maximize translational confidence
• Applying machine learning-enabled discovery strategies to improve therapeutic precision, strengthening pipeline differentiation and increasing future clinical success potential

Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in MASH drug development. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into the pioneering research and therapeutic development

•  Identification and validation of targets in complex 3d in vitro human models of MASH
• Comparison of activity throughout development across the development cycle, and the value of complex 3D human cellular in vitro models to reduce translational risk
• Integrating human-relevant ex vivo systems into validation and drug development workflows to increase biological relevance, improving decision-making and accelerating candidate progression

•  Inhibiting the pleiotropic fibrotic processes driving MASH via nonpermanent epigenetic editing (‘epi-editing’); enabling precision therapeutic intervention and expanding next-generation MASH development strategies
• Leveraging epi-editing to develop innovative and differentiated next-generation therapeutic strategies to treat steatosis and fibrosis in MASH
• Expanding pipeline opportunities by tackling undruggable targets through epi-editing gene activation or repression

• Evaluating how distinct metabolic and fibrotic disease drivers contribute to patient heterogeneity to identify high-value responder populations, enabling more targeted development strategies and improving therapeutic efficacy
• Assessing the potential of combination approaches that address complementary disease mechanisms to overcome variability in treatment response, enabling enhanced clinical benefit and improving outcomes across broader patient populations
• Leveraging clinical and biological insights to match therapies to patients most likely to benefit, improving trial precision and supporting the development of more effective and differentiated treatment paradigms

Connect with peers in a relaxed atmosphere and continue to forge new and existing relationships while exploring the latest in MASH research and advancements.

To submit a poster, please contact info@hansonwade.com

Step away from the slide decks and join informal, peer-led discussion groups. Share experiences, debate novel methodologies, and benchmark strategies with your peers in an intimate, high-value networking environment.

• Evaluating which disease drivers remain insufficiently addressed by current therapies to identify future opportunities for innovation and improve long-term patient outcomes
• Assessing emerging therapeutic mechanisms and combination approaches that may complement existing standards of care, enabling greater differentiation and expanding treatment options
• Discussing the characteristics that will define future best-in-class therapies, improving development prioritization and supporting long-term commercial and clinical success

• Evaluating how developers can differentiate new therapies within an increasingly competitive landscape to demonstrate meaningful clinical value, enabling stronger positioning and improving future adoption
• Assessing when combination approaches are likely to provide the greatest therapeutic advantage over monotherapy strategies, improving development prioritization and maximizing long-term patient benefit
• Defining the clinical, regulatory and commercial attributes required for future therapies to succeed beyond initial approval, strengthening development decision-making and supporting long-term market impact